Hartaj Singh
Stock Analyst at Oppenheimer
(1.45)
# 3,384
Out of 4,944 analysts
105
Total ratings
39.81%
Success rate
-10.92%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $19.63 | +88.49% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $560.18 | +60.66% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $119.84 | +4.31% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $393.62 | - | 17 | Dec 19, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $6.89 | +306.27% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $308.50 | +94.49% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $26.74 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $2.83 | +253.28% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.70 | +3,439.82% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.60 | +462.50% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.65 | +2,331.61% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $5.42 | +306.28% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.57 | +41,301.27% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $27.06 | +10.86% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $19.63
Upside: +88.49%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $560.18
Upside: +60.66%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $119.84
Upside: +4.31%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $393.62
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $6.89
Upside: +306.27%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $308.50
Upside: +94.49%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $26.74
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $2.83
Upside: +253.28%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.70
Upside: +3,439.82%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.60
Upside: +462.50%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.65
Upside: +2,331.61%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $5.42
Upside: +306.28%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.57
Upside: +41,301.27%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $27.06
Upside: +10.86%